OneChain Immunotherapeutics Alternatives & Competitors
12 companies similar to OneChain Immunotherapeutics — Development of CAR-T candidates for the treatment of acute lymphoblastic leukemi...
Companies similar to OneChain Immunotherapeutics
Arcellx
Arcellx is a clinical-stage biotechnology company based in Redwood City, California
Redwood City, United Stat...
Epitopea
Exploiting a new class of tumour specific antigens for cancer therapy
Montreal, Canada
LAVA Therapeutics N.V.
Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fi...
Utrecht, The Netherlands
Vect-Horus
Enhancing the transport of therapeutic and imaging agents using versatile and flexible tar...
Marseille, France
Rival Readout
Competing with OneChain Immunotherapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Laminar Pharma
Biopharmaceutical company performing discovery, rational design and initial clinical devel...
Spain
Rebirthel Co.,Ltd.
An independent biocompany, developing cellular immunotherapies for cancer, based on Kyoto.
Kyoto, Japan
Cytovia Therapeutics
We empower Natural Killer cells to fight cancer through stem cell engineering and multispe...
Aventura, United States
ALX Oncology
ALX Oncology is a clinical-stage biotechnology company advancing cancer therapies by boost...
South San Francisco, Unit...
Genespire
Biotechnology company focused on developing transformative gene therapies for patients aff...
Milan, Italy
BioTissue SA
Pioneers of Tissue Engineering and Regenerative Medicine
Switzerland
Tridek-One
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...
Paris, France
InVenis Biotherapies
Platelet-derived Regenerative Therapy for CNS Disorders
Loos, France
About OneChain Immunotherapeutics
OneChain Immunotherapeutics, founded in 2020, is a promising player in the Biotechnology and Life Sciences sectors. This spin-off from the Josep Carreras Leukemia Research Institute and ICREA focuses on developing CAR-T candidates for treating acute lymphoblastic leukemia and other hematological malignancies. The compa...
Development of CAR-T candidates, Clinical Studies
Cancer Patients, Healthcare Providers, Research Institutions
CAR-T Therapy, Hematological Malignancies, Acute Lymphoblastic Leukemia, Immunotherapy, Personalized Medicine, Leukemia Research, Antigen Targeting, Biomedicine, Innovation, Research And Development, Spin-off Company, Institute Collaboration, Hematology, Oncology
B2B, B2C, B2D
Licensing, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around OneChain Immunotherapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at OneChain Immunotherapeutics on 11 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
